SALZSTADT – (BUSINESS WIRE) – Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for developing diagnostic tests, announced today that the company's groundbreaking Co-Diagnostics CoPrimer ™ technology was unveiled at the International Plant & Animal Genome XXVIII Conference, January 11-15, 2007 becomes San Diego, CA.
A representative of Bayer – Crop Science presented the evaluation of BHQplex ™ CoPrimers in flexible PCR-based genotyping in a lecture on Monday, January 13, entitled "CoPrimer Assays for Multiplex PCR". The ability of the patented technology enable robust and flexible multiplexing for PCR-based genotyping in multiple assays. This included successfully testing their performance in many different combinations and plex levels with qPCR, endpoint and digital PCR. BHQplex CoPrimers use the company's patented CoPrimer technology, which is distributed by LGC Biosearch and covers over 200 countries.
The company intends to provide additional information about the meaning of these results after the presentation.
More information about the PAG conference can be found on the conference website.
About Co-Diagnostics, Inc .:
Utah-based Co-Diagnostics, Inc. is a molecular diagnostics company that develops, manufactures, and markets a new, state-of-the-art diagnostic technology. The company's technology is used for tests that detect and / or analyze nucleic acid molecules (DNA or RNA). The company also uses its proprietary technology to develop specific tests to locate genetic markers for industries other than infectious diseases and to license the use of these tests to specific customers.
This press release contains forward-looking statements. Forward-looking statements can be identified by words such as "believes", "expects", "estimates", "intends", "can", "plans", "will" and similar expressions or the negative of these words. Such forward-looking statements are based on facts and conditions as at the date such statements were made and on predictions about future facts and conditions. Forward-looking statements in this press release may include statements regarding: (i) use of financing proceeds, (ii) expansion of product sales, (iii) acceleration of initiatives in certain industries or markets, (iv) capitalization and runway, required to progress the company's products and markets, (v) higher short-term sales, (vi) flexibility in managing the company's balance sheet, (vii) anticipation of business expansion, and (viii) benefits in research and worldwide Accessibility of CoPrimer technology and its cost-saving and scientific advantages. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances. The actual results may differ materially from the results expected in these forward-looking statements. Readers of this press release are advised not to place undue reliance on forward-looking statements. The company is under no obligation to update any forward-looking statements related to topics discussed in this press release unless required by applicable securities law.